Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180840 | 0.87 | PTPN1 (0.47) | PTPN1KMT2AMEN1RAB9AHPGD | |
| SCHEMBL3203501 | 0.85 | PTPN1 (0.58) | PTPN1PTPN2PTPRC | |
| SCHEMBL3189034 | 0.84 | PTPN1 (0.44) | PTPN1PTPN2PTPRC | |
| SCHEMBL3191987 | 0.82 | RAB9A (0.39) | KMT2AMEN1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3200842 | 0.81 | PTPN1 (0.47) | PTPN1PTPN2 | |
| SCHEMBL3263156 | 0.77 | PTPN1 (0.39) | PTPN1PTPN2PTPRC | |
| SCHEMBL3192633 | 0.76 | PTPN1 (0.56) | PTPN1PTPN2PTPRC | |
| SCHEMBL3190740 | 0.76 | PTPN1 (0.59) | PTPN1PTPN2PTPRC | |
| SCHEMBL3260915 | 0.76 | PTPN1 (0.43) | PTPN1PTPN2PTPRC | |
| SCHEMBL3200190 | 0.76 | PTPN1 (0.40) | PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674822-B2 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | WYETH | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135488-A1 | protein tyrosine phosphatase 1B (PTP1B) modulators; type 2 diabetes, obesity; increasing insulin sensitivity; 1-Carboxymethoxy-3,8-dithia-cyclopenta[a]indene-2-carboxylic acid | PTPA, PTPRCAP, PTPRC | PTPN1 22/4885KMT2A 3165/4885MEN1 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.